🇺🇸 FDA
Patent

US 8946300

Use of rasagilline for the treatment of restless legs syndrome

granted A61KA61K2300/00A61K31/135

Quick answer

US patent 8946300 (Use of rasagilline for the treatment of restless legs syndrome) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K2300/00, A61K31/135, A61K31/16, A61K31/428